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Abstract
Guanine nucleotide-exchange factors (GEFs) stimulate guanine nucleotide exchange and the
subsequent activation of Rho-family proteins in response to extracellular stimuli acting upon
cytokine, tyrosine kinase, adhesion, integrin, and G-protein coupled receptors (GPCRs). Upon
Rho activation, several downstream events occur, such as morphological and cytokskeletal
changes, motility, growth, survival, and gene transcription. The RhoGEF Leukemia-Associated
RhoGEF (LARG) is a member of the Regulators of G-protein Signaling Homology Domain (RH)
family of GEFs originally identified as a result of chromosomal translocation in acute myeloid
leukemia. Using a novel fluorescence polarization guanine nucleotide binding assay utilizing
BODIPY-Texas Red-GTPγS (BODIPY-TR-GTPγS), we performed a ten-thousand compound
high-throughput screen for inhibitors of LARG-stimulated RhoA nucleotide binding. Five
compounds identified from the high-throughput screen were confirmed in a non-fluorescent
radioactive guanine nucleotide binding assay measuring LARG-stimulated [35S] GTPγS binding
to RhoA, thus ruling out non-specific fluorescent effects. All five compounds selectively inhibited
LARG-stimulated RhoA [35S] GTPγS binding, but had little to no effect upon RhoA or Gαo [35S]
GTPγS binding. Therefore, these five compounds should serve as promising starting points for the
development of small molecule inhibitors of LARG-mediated nucleotide exchange as both
pharmacological tools and therapeutics. In addition, the fluorescence polarization guanine
nucleotide binding assay described here should serve as a useful approach for both high-
throughput screening and general biological applications.
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Introduction
The Rho-family of small GTPases are a main subset of the Ras superfamily of small
GTPases (∼ 20-25 kDa) 1. The Rho-family of GTPases is further subdivided into ten
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subgroups based upon their identity. In this work, we focus on the small GTPase RhoA,
which is a member of the Rho subgroup (RhoA, RhoB, and RhoC) within the Rho-family of
proteins. In the cell, Rho GTPases are activated upon ligand activation of cell surface
receptors, such as cytokine, tyrosine kinase, adhesion, integrin, and G-protein coupled
receptors (GPCRs) 2. As a result, this causes Rho GTPases to switch from their inactive
GDP-bound form to their active GTP-bound form leading to various downstream cellular
events, such as cytoskeletal and morphological changes, migration, growth, survival, and
gene transcription 1.
The activation state of Rho GTPases is controlled by several classes of regulatory proteins.
The GTPase-activating proteins (GAPs) catalyze GTP hydrolysis by active Rho proteins
leading to their inactivation. The guanine nucleotide-dissociation inhibitors (GDIs) sequester
GDP-bound Rho GTPases in the cytosol, thus preventing their subcellular localization to the
plasma membrane and activation. Lastly, the guanine nucleotide exchange factors (GEFs)
stimulate the exchange of GTP for GDP upon Rho GTPases leading to their activation, and
are the focus of this work. There are more than sixty identified human Rho GEFs that
specifically activate Rho GTPases 1.
Rho GEFs are characterized by their Dbl homology (DH) (∼200 residues) and C-terminal
adjacent pleckstrin homology (PH) (∼100 residues) domains. DH domains are primarily
responsible for catalyzing the guanine nucleotide exchange (GTP for GDP) upon Rho
GTPases 1. PH domains are responsible for membrane localization of Rho GEFs and aid the
DH domain in catalysis of guanine nucleotide exchange 1. The focus of this work is upon
the leukemia-associated RhoGEF (LARG), which was originally identified as a
chromosomal translocation fusion protein to mixed-lineage leukemia (MLL) in a patient
with acute myeloid leukemia 3. LARG is a member of the regulators of G-protein signaling
homology domain (RH) containing RhoGEF family of proteins (LARG, p115- RhoGEF,
PDZ-RhoGEF) 4. This family of Rho GEFs is linked to Rho-dependent signaling pathways
controlled by heterotrimeric G-protein coupled receptors coupled to the Gα12 and Gα13
subunits, such as the lysophosphatidic acid, bombesin, and thrombin receptors 4-7.
LARG is an important regulatory protein in several clinical disorders. Considering its
original identification in acute myeloid leukemia, LARG has largely been thought to be a
key player in cancer progression. In conjunction with the Raf-1 kinase, LARG has been
shown to transform mouse fibroblasts 8. It has also been shown to play a role in cell
migration and growth of head and neck squamous cancer cells through adhesion and
tyrosine kinase receptor interaction and subsequent RhoA activation 9. LARG has also been
shown, through overexpression and siRNA knockdown, to play a role in thrombin and
bombesin receptor-mediated prostate cancer cell morphology changes and migration 6, 7. In
addition to cancer, LARG has been implicated in lectin signaling in dendritic cells, which is
important in sequestration of human immunodeficiency virus (HIV) virions leading to the
progression of the HIV disease 10. LARG also has been shown to play a role in vascular
biology and calcium signaling. It has been directly linked to a role in salt-induced
hypertension in transgenic mice and it has been speculated to play a role in erectile
dysfunction 11-13. As a result, considering the implication of LARG in multiple diseases
and disorders, it is an attractive molecular target for drug discovery.
Currently, there are limited pharmacological tools targeting RhoGEFs and RhoGTPases. To
date, most of the efforts have focused upon inhibiting the lipid modification of RhoGTPases,
which is necessary for plasma membrane localization and activation. The inhibitors of this
modification include farnesyltransferase and geranylgeranyl transferase inhibitors and the
cholesterol-lowering statin drugs 14, 15. Unfortunately, these inhibitors and drugs are not
specific to RhoGTPases, which complicates the mechanistic interpretation of results using
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these inhibitors. To date, there are only two reported specific inhibitors of RhoGTPases.
Both inhibitors selectively inhibit Rac1 but they differ in their mechanism of inhibition. The
inhibitor NSC23766 (IC50, ∼50 μM) inhibits by binding to the GEF binding pocket on Rac1
16, and EHT 1864 (Kd, 40 nM) inhibits by binding to the nucleotide binding pocket on Rac1
17, 18. Although, there are a few examples of selective RhoGTPase inhibitors, there are no
published examples to date of inhibitors that target RhoGEFs.
Therefore, in this study, we performed a ten-thousand compound high-throughput screen for
small molecule inhibitors of LARG-stimulated RhoA nucleotide exchange. In order to do
this screen, we first developed a novel fluorescence polarization (FP) RhoA nucleotide
binding assay using BODIPY-TR-GTPγS. We chose fluorescence polarization rather than
both the standard fluorescence intensity and radioactive [35S] GTPγS binding approaches
because it proved to be more environmentally friendly, robust, reliable, and reproducible.
Out of ten-thousand compounds screened, six compounds were confirmed to inhibit LARG-
mediated guanine nucleotide exchange. Out of these six compounds, five confirmed in a
non-fluorescent, radioactive [35S] GTPγS guanine nucleotide binding assay with IC50 values
in the micromolar range. These compounds showed selectivity for LARG-stimulated RhoA
[35S] GTPγS binding by having little to no effect upon RhoA and Gαo [35S] GTPγS binding.
Therefore, as a result of the high-throughput screen with this novel fluorescence polarization
guanine nucleotide binding assay, five promising compounds were identified as inhibitors of
LARG-stimulated RhoA nucleotide binding. Therefore, with further synthetic chemistry
follow-up, these compounds may lead to useful inhibitors of LARG-stimulated RhoA
nucleotide binding for both research and therapeutic purposes.
Materials and Methods
Plasmids, Protein Purification, and Chemical Reagents
Human RhoA (residues 1-189, C189S) was expressed in Escherichia coli as described
previously 19. Human LARG encoding the DH/PH domains (residues 765-1138) was
expressed in Escherichia coli as described previously 20. Gαo expression and purification in
Escherichia coli was described previously 21. BODIPY® Texas-Red (TR) guanosine 5′-O-
(3-thiotriphospahte) (GTPγS) was obtained from Molecular Probes – Invitrogen (Eugene,
OR). [35S] GTPγS was obtained from Perkin Elmer (Waltham, MA). GTPγS was obtained
from EMD Biosciences (San Diego, CA). The non-ionic detergents IGEPAL and Lubrol
were from Sigma (St. Louis, MO). The 10,000 structurally diverse chemical compounds
were obtained from ChemBridge (San Diego, CA) as part of the collection of the University
of Michigan Center for Chemical Genomics (CCG). The chemical similarity was low – at
80% similarity calculated with the ICMPro (Molsoft LLC, La Jolla, CA) clustering
algorithm there were 4390 clusters with a median size of 1 compound and mean size of 2.28
compounds.
Guanine Nucleotide Binding Fluorescence Polarization Assays
Exchange buffer (20mM Tris HCl pH 7.5, 150 mM NaCl, 10 mM MgCl2, 10% Glycerol,
0.01% IGEPAL, freshly prepared 1mM DTT) was added to each well of a black 96-well
plate. Purified full-length human RhoA(C189S), purified DH/PH domain of human LARG,
and BODIPY-FL-GTPγS or BODIPY-TR-GTPγS were added sequentially to each well to a
final volume of 100 μL per well. Fluorescein or Texas-Red fluorescence polarization was
read in a Victor2 plate reader using excitation at 485 nm and emission at 535 nm for
fluorescein, or an excitation at 560 nm and emission at 630 nm for Texas-Red. The
measured values of polarization (mP) were calculated by using the formula: mP = (F‖ - F⊥)/
(F‖ + F⊥) where F‖ = fluorescence intensity parallel to the excitation plane, F⊥ =
fluorescence intensity perpendicular to the excitation plane. The statistical Z′ – factor used
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to assess assay suitability for high-throughput screening was calculated by using the
formula, Z′ = 1 − [(3σc+ + 3σc-)/(|μc+ - μc-|)] where σ = standard deviation, μ = mean, c+ =
with LARG, c- = without LARG).
RhoA [35S] GTPγS Guanine Nucleotide Binding Assay
The indicated concentrations of purified DH/PH domain of human LARG (0.5-2 nM, final)
are added to a tube in Buffer I (20 mM Tris pH 7.5, 1 mM EDTA, 1 mM DTT, 50 mM
NaCl, 0.1% Lubrol, 2 mM MgCl2) in a final volume of 180 μL. To this mixture, 45 μl of
purified human RhoA (C189S) in Buffer I is added to yield a final concentration of 500 nM.
The reaction was initiated by adding 225 μL of 2X Binding Buffer (100 mM Tris pH 7.5, 1
mM EDTA, 2 mM DTT, 100 mM NaCl, 10 mM MgCl2, 5 μM GTPγS, 0.1% Lubrol, 6.75
μCi [35S] GTPγS) for a final reaction volume of 450 μL. Reaction mixtures were incubated
at room temperature for 1, 5, 10, 30, 60, 120, and 180 minutes. 50 μL of reaction mixture
was removed and diluted in a tube containing 4 mL of ice-cold Wash Buffer (20 mM Tris
pH 8.0, 100 mM NaCl, 25 mM MgCl2) to stop the reaction. An additional 4 mL of Wash
Buffer was added to the tube and the sample filtered on a BA85 25mm nitrocellulose filter
using a Hoeffer filtration system. Filters were washed two times with 4 mL of Wash Buffer.
Filters were dried under a heat lamp for 5 minutes. Filters were counted in 4 mL of
scintillation fluid (Scintiverse) for 1 min using a Beckman LS 5801 Scintillation Counter.
The identical method was followed for RhoA [35S] GTPγS binding studies without LARG,
except reaction mixtures were incubated at room temperature for 1, 5, 10, 30, 60, 130, and
180 minutes.
Gαo [35S] GTPγS Guanine Nucleotide Binding Assay
Purified Gαo was diluted to a final concentration of 10 μM in 180 μL of Gαo dilution buffer
(10 mM HEPES pH 7.7, 1mM EDTA, 0.1% Lubrol, 1 mM DTT). [35S] GTPγS binding was
initiated by adding 180 μL of Gαo binding cocktail (50 mM HEPES pH 7.7, 1 mM EDTA,
40 mM MgCl2, 200 mM NaCl, 2 μM GTPγS, 6.75 μCi [35S] GTPγS, 1 mM DTT) and
incubated at room temperature for 1, 5, 10, 30, 60, 90, and 120 minutes. 40 μL of the
reaction mixture was diluted in a tube containing 4 mL of ice-cold Wash Buffer (20 mM
Tris pH 8.0, 100 mM NaCl, 25 mM MgCl2). This reaction mixture was then filtered on a
BA85 25 mm nitrocellulose filter using a Hoeffer filtration system. Filters were washed
twice with 4 mL of Wash Buffer, then dried under a heat lamp for 5 minutes. Filters were
counted in 4 mL of scintillation fluid for 1 min using a Beckman LS 5801 Scintillation
Counter.
High-Throughput LARG-stimulated RhoA Guanine Nucleotide Binding Fluorescence
Polarization Screen
Using a Multidrop 384 (Thermo), exchange buffer was added to each well of a low volume
black 384 well plate (Corning, cat.#: 3676); - 20 μL was added for the positive control wells
(i.e. no LARG) and 15 μL was added to all other wells. Using a 384-well pin tool on a
Biomek FX liquid handling workstation (Beckman Coulter), approximately 250 nL of
compound (stock concentration 0.75-4 mM - ChemBridge) or DMSO, for control wells, was
added (producing final compound concentrations of ∼ 6-30 μM and 0.8% DMSO). Plates
were then incubated at room temperature for 5 minutes. Using a Multidrop micro (Thermo)
5 μL of purified DH/PH domain of human LARG in exchange buffer was added to the wells
of the 384-well plate to produce a final concentration of 100 nM. Plates were then incubated
for 5 minutes at room temperature. Using a Multidrop micro 5 μL of purified human RhoA
(C189S) in exchange buffer was added to produce a final concentration of 2 μM. Plates were
then incubated for 2 minutes at room temperature. The reaction was initiated by using a
Multidrop micro to add 5 μL of BODIPY-TR GTPγS in exchange buffer to a final
concentration of 500 nM and a final reaction volume of 30 μL. Plates were incubated for 20
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minutes at room temperature, then read for fluorescence polarization with a PHERAstar
(BMG LabTech) plate reader with a 575 nm band pass excitation filter, a 620 nm band pass
emission filter, a dichroic mirror, and a dual emission beam splitter to permit simultaneous
recording of parallel and perpendicular fluorescence readings. Plates were individually
incubated after each addition so that all plates would be read in the PHERAstar plate reader
precisely at 20 minutes after GTPγS addition (i.e. prior to saturation of the reaction time
course). For follow-up dose-response studies of the primary hits, the same method was
carried out as for the high-throughput screen, except reagents were added by hand with a
multichannel pipet. In addition, compounds were added to the wells of the 384 well plate
using serial two-fold dilutions over a range of concentrations between 100 μM and 3.125
nM.
Compound Properties
Compound properties were calculated with ChemAxon JChem software. The LogP value
method is described in Viswanadhan et al. 22.
Results
Fluorescence Polarization Guanine Nucleotide Binding Assay
In order to study RhoA guanine nucleotide exchange in vitro, we used a novel fluorescence
polarization guanine nucleotide binding assay adapted from the standard fluorescence
intensity guanine nucleotide binding assay described previously by our laboratory 23, 24.
This fluorescence polarization assay utilizes the non-hydrolysable fluorescently labeled
guanine nucleotide BODIPY-GTPγS fluorophores. LARG-stimulated BODIPY-GTPγS
fluorophore binding to RhoA results in fluorescence polarization that can be read by a plate
reader (Fig. 1A). The structures of the BODIPY-GTPγS fluorophores used in this study are
shown in figure 1C.
Due to the importance of having a robust and reproducible assay for high-throughput
screening, we compared the suitability of nucleotide binding to RhoA measured by
fluorescence intensity (data not shown) versus fluorescence polarization (Fig. 2). Although
both intensity and polarization assays gave signals for RhoA nucleotide binding, only the
fluorescence polarization assay (Z′ – factor = 0.7) gave suitably reproducible data
appropriate for doing a high-throughput screen (Fig. 2). The fluorescence polarization assay
takes into account fluorescence that is both parallel and perpendicular to the excitation plane
and the ratiometric nature of the measurement cancels many contributions to the noise 25.
This most likely accounts for the difference between the Z′-factors of the two assays. As a
result, fluorescence polarization should be a useful assay for high-throughput screening for
small molecule inhibitors of GEF stimulated small GTPase guanine nucleotide binding. In
addition, the assay has recently been used for general biological applications studying GEF
activity upon small GTPases 26.
Comparison between the Fluorescence Polarization and [35S] Guanine Nucleotide Binding
Assays
The standard [35S] GTPγS nucleotide binding assay is generally not suitable for high-
throughput screening due to time consumption, accumulation of environmental hazardous
waste, and the complexity of adapting the assay to a 384-well plate format. Therefore, we
chose the fluorescence polarization assay to use for our high-throughput screen. We found
that in both assays LARG was able to stimulate RhoA (C189S) nucleotide binding in a
concentration-dependent manner (Fig. 3A-B). However, the time courses for saturation in
the two methods differed with saturation occurring at 40 minutes for the fluorescence
polarization assay, and 180 minutes for the [35S] radioactive assay. The basal rate constant
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for nucleotide exchange was slower with the [35S] GTPγS method. The faster kinetics of
binding in the fluorescence polarization assay may be due, in part, to: higher concentrations
of RhoA and nucleotide, the lower amount of nucleotide relative to the amount of RhoA, the
higher NaCl or MgCl2 concentrations or the non-native BODIPY nucleotide structure in the
fluorescence polarization assay. However, plotting the rate constants on a graph both give a
linear plot (Fig. 3C-D) suggesting that both the fluorescence polarization and radioactive
nucleotide binding assays are appropriate for measuring GEF-stimulated nucleotide binding
to the Rho-family of proteins.
High-Throughput Screen for Inhibitors of LARG-stimulated RhoA Nucleotide Exchange
A ten-thousand diverse chemical compound collection from ChemBridge was used to screen
for small molecule inhibitors of LARG-stimulated RhoA nucleotide exchange. The
fluorescence polarization guanine nucleotide binding assay utilizing the purified DH/PH
domain of LARG and RhoA (C189S) was used for the screen. Compounds were added to a
black 384-well low volume plate containing exchange buffer with a 384-well pin tool on the
Biomek FX workstation. Then, the purified DH/PH domain of LARG, RhoA (C189S), and
BODIPY-TR-GTPγS were added to the plate in sequential order. After a twenty minute
incubation (non-saturating time point), polarization was read in a PHERastar plate reader as
shown in figure 4A. The assay was tested for its suitability for high-throughput screening
and reliability by using the Z′-factor statistical measurement. Utilizing purified RhoA
(C189S) alone plus DMSO (positive control for screen – 100% inhibition) and the purified
DH/PH domain of LARG and RhoA (C189S) plus DMSO (negative control for the screen –
0% inhibition), the Z′-factor in this high-throughput screening format was determined to be
0.52 indicating a suitable and reliable screen (Fig. 4B) 27. While many FP-type screens give
higher Z′ factors than this, consideration should be taken of the fact that this is a kinetic
assay done at a pre-saturation time point so it would not be expected to have quite as good a
Z′ as a standard equilibrium FP binding assay.
Compounds which showed more than 30% inhibition or values of % inhibition more than 3
standard deviations from the negative control were considered to be actives. Figure 4C
shows 19 hits from the 30% inhibition criterion and an additional 12 were found with the 3
standard deviation criterion providing 31 initial actives (or a “hit” rate of 0.3%). There were
several plates with clusters of compounds that just met the cutoff and they were retested in
duplicate using the primary screening assay methodology. Any that confirmed in either of
the two measurements were retained in the actives list and were studied further in a
concentration response study using the BODIPY-TR-GTPγS fluorescence polarization
assay. Out of those thirteen compounds, seven (0.07% - hit rate) did inhibit in this follow-up
assay and six compounds did not (<50% inhibition at 100 μM) (Fig. 4D). Of the 7 confirmed
actives, six were available for re-supply from ChemBridge for follow-up studies. The three
most potent of these six compounds, CCG-14631 (4-{5-[(4,6-dioxo-2-sulfanylidene-1,3-
diazinan-5-ylidene)methyl]furan-2-yl}-N-(1,3-thiazol-2-yl)benzene-1-sulfonamide)
(Chembridge, cat.#: 6192873), CCG-12529 (7-(3-nitrophenyl)-8-
azatricyclo[7.4.0.0ˆ{2,6}]trideca-1(13),3,9,11-tetraene-10-carboxylic acid) (ChemBridge,
cat.#: 5584249) and CCG-5849 (4-amino-2-(5-amino-1,3-benzothiazol-2-yl)phenol)
(ChemBridge, cat.#: 5312639)) had IC50 values between 3 μM and 10 μM (Fig. 4D, Table
1). The three remaining compounds, CCG-14113 ((N′Z)-2-[(3-methylphenyl)amino]-N′-
[(2,4,6-tribromo-3-hydroxyphenyl)methylidene]acetohydrazide) (ChemBridge, cat#:
6119878), CCG-13528 ((5Z)-3-(2H-1,3-benzodioxol-5-yl)-2-imino-5-{[5-(2-
nitrophenyl)furan-2-yl]methylidene}-1,3-thiazolidin-4-one) (ChemBridge, cat.#: 5354792),
were less potent with IC50 values between 32 μM and 65 μM (Fig. 4D, Table 1) in the
fluorescence polarization assay.
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Secondary Screen in [35S] GTPγS Radioactive Guanine Nucleotide Binding Assay
As mentioned previously, a potential mechanism for false positives in a fluorescence-based
assay is quenching of the fluorescence signal. To address this concern, we utilized the
traditional radioactive [35S] GTPγS guanine nucleotide filter binding assay as a secondary
follow-up assay for our 6 confirmed active compounds. For these experiments, we utilized a
time point of twenty-five minutes, prior to saturation on the kinetic curve in figure 5A. Five
of the six candidate compounds showed dose-dependent inhibition in the [35S] GTPγS
guanine nucleotide binding assay. The one compound that was not active in the radioligand
assay showed a marked effect on the total fluorescence as calculated by
Fparallel+2*Fperpendicular (54% reduction). The three most potent compounds in this
radioactive-based assay, CCG-13528, CCG-14631, and CCG-7167, had IC50 values
between 4 μM and 7 μM (Fig. 5B, Table 1). The other two compounds, CCG-14113 and
CCG-12529, were less potent with IC50 values around 30 μM (Table 1). These IC50 values
for several of the compounds differ between the [35S] GTPγS and fluorescence polarization
methods. These differences can most likely be attributed to experimental differences
between the assays such as NaCl and MgCl2 concentrations and the different nature of the
detergent or nucleotide used. Despite these differences, the fact that 5 of the 6 tested
compounds did show some activity in the [35S] GTPγS method is encouraging.
CCG-13528 and CCG-14631 satisfy all of Lipinski's rules-of-five for chemical compounds
that have the most potential in becoming a drug with respect to their physical properties 28.
CCG-7167 had only one violation of Lipinski's Rule of Five due to a partition coefficient
(log P) of 5.52 (Table 1). Interestingly, our three most potent compounds are all extended
aromatic molecules. They have 4 (CCG-14631) or 5 (CCG-13528, CCG-7167) rings and are
16 (CCG-13528) or 18 (CCG-14631, CCG-7167) atoms in length (Fig. 5C). This suggests a
potential pharmacophore for inhibiting LARG-stimulated RhoA nucleotide exchange which
may be explained by the long shallow pocket of the LARG/RhoA interaction site 29.
Compound Selectivity for LARG-stimulated RhoA nucleotide binding
Inhibition of LARG stimulation of RhoA nucleotide exchange can occur by two primary
mechanisms. The compound could directly inhibit GTP binding to RhoA or it could block
LARG-mediated nucleotide exchange. Determining the exact mechanism of the inhibition of
LARG-stimulated RhoA nucleotide exchange is beyond the scope of the present study,
however, we did determine whether the compounds inhibited GTP binding or LARG-
mediated exchange in the [35S] GTPγS guanine nucleotide binding assay. [35S] GTPγS
binding to the small GTPase RhoA and the G-protein alpha subunit Gαo was determined at
sixty minutes and twenty-five minutes, respectively. (Fig. 6A-B). [35S] GTPγS binding to
RhoA and Gαo was tested in the absence of GEFs to determine whether the compounds
inhibited GTP binding directly. As expected, all five compounds inhibited LARG-stimulated
RhoA [35S] GTPγS binding (≥ 50%) yet they had only modest or no effect upon direct
RhoA and Gαo [35S] GTPγS binding at a maximal concentration of 100 μM (Fig. 6C).
Therefore, the five compounds identified in the high-throughput screen described here do
appear to inhibit the LARG-mediated nucleotide exchange in some manner.
Discussion
Radioactive and fluorescence assays are the primary approaches utilized to measure guanine
nucleotide exchange of small GTPases. These approaches typically use radioactive [3H] or
[35S] or fluorescent N-methyl-3′-O-anthranoyl (MANT) and boron dipyrromethene
(BODIPY) analogs of guanine nucleotides. They either measure binding of the non-
hydrolysable GTP analog, GTPγS, to G-proteins or release of labeled GDP from G-proteins
23, 24, 30. Upon nucleotide exchange, the guanine nucleotide analogs yield either a
Evelyn et al. Page 7













measurable radioactive or fluorescence signal. Here, we describe a novel assay that utilizes
fluorescence polarization rather than the standard fluorescence intensity approach to
measure LARG-stimulated RhoA nucleotide binding. We chose the fluorescence
polarization assay due to its better, initial baseline kinetics, signal to noise ratio, and Z′-
factor (data not shown). The Z′-factor measures the reliability of a positive screening hit
based on the dynamic range and intrinsic variability of the assay 27, 31. The Z′-factor for the
fluorescence polarization assay was 0.7 in pilot studies and showed a sustained level of 0.52
in our 10,000 compound screen. This should be sufficient for high-throughput screening,
and for general biological applications.
One major issue in fluorescence-based high-throughput screening assays is the type of
fluorophore one chooses. The most commonly used fluorophores used to label guanine
nucleotides, MANT and BODIPY-FL, have the drawback of being detected in the blue and
green regions of the electromagnetic spectrum 32. This enhances the chance of false
positives in high-throughput screens due to compounds absorbing light in this region of the
electromagnetic spectrum. Therefore, in the work described here, we utilize a GTPγS
nucleotide labeled with the BODIPY-TR fluorophore (Fig. 1C), which is detected in the red
region of the electromagnetic spectrum. This, along with the use of the ratiometric FP
method, should decrease the chance of false positives due to non-specific compound
absorbance. We compared the fluorescence polarization BODIPY-TR-GTPγS binding assay
as a measure of nucleotide exchange with the traditional radioactive [35S] GTPγS binding
assay. We found both assays to be able to show concentration-dependent LARG-stimulated
RhoA nucleotide binding and linear rate constants with respect to LARG concentration (Fig.
3). However, the two methods were different with respect to experimental conditions (i.e.
buffers, protein concentrations, type of detergent and nucleotide) and reaction time. Despite
the differences between assays, we chose the fluorescence polarization assay for a high-
throughput screen for inhibitors of LARG-mediated nucleotide exchange based upon its
reliability, adaptability to a 384-well plate format, lack of production of environmental
waste, and time efficiency.
There are several ways that one can molecularly target the function of RhoGEFs and Rho
GTPases. One can inhibit the membrane localization of Rho GTPases through blockade of
lipid modifications. Interestingly, using a high-throughput screening approach, Peterson et.
al. describe the identification of a geranylgeranyl transferase type I small molecule inhibitor
(IC50 – 10 μM) that inhibits Rho GTPase function 33. Another way to obstruct Rho function
is through small molecule stimulation of GAPs, in order to stimulate intrinsic hydrolysis of
Rho GTPases promoting inhibition of function. Small molecule stabilization of the
association of GDIs with Rho GTPases can also be effective in disrupting the activation of
Rho GTPases by preventing membrane localization 1. Also, small molecule inhibition of
GEFs would be effective in disrupting Rho function by preventing activation of Rho
GTPases. Function can be abolished by directly targeting the RhoGTPase. Interestingly, Gao
et.al. describe the identification of a direct small molecule inhibitor of Rac1, NSC23766
(IC50 – 50 μM), through structure-based virtual screening approach 16. Another direct Rac1
inhibitor, EHT 1864 (Kd – 40 nM), selectively inhibits Rac1 through blocking the binding
of the guanine nucleotide to Rac1 17, 18. Also, we recently identified an inhibitor
downstream in the rho-stimulated gene transcription pathway using a cell-based luciferase
reporter screen 34. As a result, we describe here a fluorescence polarization high-throughput
screen of a ChemBridge diverse chemical library for inhibitors of LARG-mediated RhoA
nucleotide exchange.
LARG was originally discovered as a chromosomal translocation fusion to MLL in a patient
with Acute Myeloid Leukemia 3. Therefore, from its initial identification, LARG has been
linked to cancer. LARG gene expression was shown to be upregulated in patients with the
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preleukaemic disorder Scwachman-Diamond syndrome (SDS) 35. LARG was first shown to
have oncogenic activity in a NIH3T3 transformation assay 8. Since then, LARG- mediated
Rho activation has been shown to be important in prostate cancer (PC-3) and breast cancer
(MDA-MB-435) cell morphology, motility, and invasion upon extracellular stimulation by
the GPCR ligands bombesin, thrombin, and lysophosphatidic acid 6, 7, 36. In addition,
LARG interaction with the adhesion receptor, CD44, or tyrosine kinase receptor, epidermal
growth factor receptor (EGFR) and subsequent Rho activation has been shown to be
necessary for cytoskeletal modification, motility, and invasion in head and neck squamous
cell carcinoma (HSC-3) cells 9. Therefore, a small molecule inhibitor of LARG-mediated
RhoA nucleotide exchange would be a useful tool to elucidate cancer mechanisms and as a
potential cancer therapeutic.
In addition to cancer, LARG also has the potential to play an important role in HIV or
vascular diseases. LARG has been shown to be upregulated in rat vascular smooth muscle
by Angiotensin II and it is basally expressed in rat corpus cavernosum, thus potentially
playing a vital role in contraction and calcium sensitization 11, 13, 37. Recently, LARG was
determined to be the key RhoGEF involved in the development of salt-induced hypertension
12. Interestingly, Hodges et. al. describe a role for LARG in HIV-1 pathogenesis via
forming a complex with the c-type lectin receptor, DC-SIGN 10. Therefore, small molecule
inhibition of LARG-mediated RhoA nucleotide exchange may prove to be useful in the
development of pharmacological tools and therapeutics for better understanding of disease
pathogenesis and treatment of diseases and disorders, including HIV, hypertension, and
erectile dysfunction (ED).
The five compounds identified in this study would be of interest for further development
based on the multiple diseases and disorders that an inhibitor of LARG-mediated RhoA
nucleotide exchange may have a positive impact upon. All five compounds have potency in
the micromolar range, which make them reasonable candidates for synthetic chemistry
follow-up. In addition, the compounds do not inhibit GTP binding to RhoA or to Gαo.
Therefore, they most likely inhibit LARG-mediated nucleotide binding by: (i) binding to the
LARG binding surface on RhoA, (ii) binding to the RhoA binding surface on LARG, (iii)
allosterically binding to either LARG or RhoA causing a conformational change, (iv)
binding to both RhoA and LARG, or (v) covalently modifying RhoA or LARG. Further
development, specificity studies, and mechanistic characterization are still needed, but the
compounds identified in this study inhibit LARG-mediated RhoA nucleotide exchange with
micromolar potency in vitro.
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Fig. 1. GTPase Cycle, Mechanisms of Inhibition, and Structure of GTP Analogs
(A) In its inactive form, the small GTPase RhoA is bound to both GDP and Mg+2. Upon the
binding of the DH/PH domain of the RhoGEF LARG (which is the catalyst of the guanine
nucleotide exchange reaction), a conformational change occurs in the switch regions of the
small GTPase RhoA causing an intermediate to form that is free of nucleotide and Mg+2.
This enables the higher concentrated nucleotide GTP and Mg+2 to bind to the small GTPase
RhoA. In our in vitro assays described in this report, we utilize the BODIPY-Texas Red
fluorescently labeled or [35S] radioactive labeled non-hydrolysable form of the guanine
nucleotide, GTPγS. As a result, the GTP-bound RhoA can be released from the RhoGEF
LARG in an active state. In our in vitro assays described in this report, this results in a
polarized light signal in our fluorescence polarization assay, or a radioactive signal in our
[35S] radioactive assay that can be quantitatively measured. (B) There are several potential
mechanisms of inhibition of LARG stimulated RhoA nucleotide binding, which include: (I)
competitive inhibition at the site of interaction between LARG and RhoA, (II) allosteric
inhibition by drug binding to LARG, (III) competitive inhibition at the site of nucleotide
binding, or (IV) allosteric inhibition by drug binding to RhoA. (C) The chemical structures
of the three non-hydrolysable forms of the guanine nucleotide, GTPγS, used in both the
fluorescence and radioactive in vitro assays described in this report are depicted.
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Fig. 2. Fluorescence Polarization RhoA Nucleotide Binding Assays
Purified DH/PH domain of LARG (200 nM) stimulated nucleotide stimulation of purified
RhoA (C189S) (2μM) utilizing BODIPY-FL-GTPγS (1μM) and BODIPY-TR-GTPγS (1
μM). Values were measured in a Victor2 plate reader as described in the Materials and
Methods. (A) LARG-dependent nucleotide binding to RhoA (C189S) (□) (2 μM) stimulated
by LARG [50 nM (Δ), 100 nM (◊), 200 nM (○)] utilizing BODIPY-TR-GTPγS (1 μM) was
measured over a time course of 55 minutes for fluorescence polarization by using a Victor2
plate reader as described in the Materials and Methods. (B) Fluorescence polarization
measurements were taken from 48 wells not containing LARG [- LARG (●)] and 48 wells
containing LARG [+ LARG (▲)] in a 96-well black plate after incubating for 20 minutes at
room temperature. Data in panels A and B represent experiments performed in duplicate.
Data in panel A and B are represented as mP polarization values. The Z′ – factor was
calculated for the fluorescence polarization measurement. The Z′ – factor for the
fluorescence polarization assay was 0.7 indicating an assay suitable for high-throughput
screening.
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Fig. 3. Dose-Dependent LARG-stimulated RhoA Nucleotide Binding
(A) Dose-dependent nucleotide binding to RhoA (C189S) (□) (2 μM) stimulated by LARG
[50 nM (Δ), 100 nM (◊), 200 nM (○)] utilizing BODIPY-TR-GTPγS (500 nM) was
measured over a time course of 40 minutes in a Victor2 plate reader as described in the
Materials and Methods. (B) Dose-dependent nucleotide binding to RhoA (C189S) (■) (500
nM) stimulated by LARG [0.5 nM (▲), 1nM (✦), 2nM (●)utilizing [35S] GTPγS was
measured over a time course of 180 minutes by a Beckman LS 5801 Scintillation Counter as
described in the Materials and Methods. The black dotted vertical line and the solid black
circles indicate the time point (incomplete saturation point) used for the high-throughput
screen. (C, D) Rate constants for the reactions were plotted versus the concentration of
LARG yielding a linear plot for both the FP and radioactive binding assays. A linear
regression plot was performed using Graphpad Prism 5, yielding R2 values of 0.9. Rate
constants were calculated using the one phase exponential association equation Y = Ymax *
(1-exp(-k*X) (k = rate constant for the reaction). Data in panel A were measured in
duplicate and are representative data of N = 3. Data in panel A were background subtracted
from BODIPY-TR-GTPγS fluorescence alone. Data in panel B represent the mean ± SEM
of three separate experiments (N = 3).
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Fig. 4. Fluorescence Polarization Screen for Inhibitors of LARG-stimulated RhoA Nucleotide
Binding
(A) Schematic of the protocol used for the 10,000 ChemBridge diverse chemical compound
high-throughput screen (HTS) as described in the Materials and Methods. All samples,
compounds and controls, contain 0.8% DMSO. (B) Control samples run on each plate
include (100 nM) LARG as a negative (0% inhibition) control (●) and no LARG as a
positive (100% inhibition) control ( ). The statistical Z′ – Factor measurement for the HTS
was calculated to be 0.52 for this entire screen indicating suitable reproducibility. (C) Data
from the 10,000 ChemBridge compound HTS (CCG compounds 5029-15028) are shown (●)
with a 30 percent inhibition line indicated in red. (D) Dose-response follow-up of the
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positive hits from the HTS in the LARG-stimulated RhoA nucleotide BODIPY-TR-GTPγS
binding assay measured at a time point of 20 minutes. Data in panel D were measured in
duplicate and are represented as percent change from the +LARG negative control (0%)
comapred to the no LARG positive control (100%).
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Fig. 5. Dose Response Inhibition of LARG-stimulated RhoA [35S] GTPγS Binding by HTS Hits
(A) Time-course of guanine nucleotide binding of RhoA (C189S) (■) (500 nM) stimulated
by LARG [2nM (●)] utilizing [35S] GTPγS was measured over a time course of 180 minutes
by a Beckman LS 5801 Scintillation Counter as described in the Materials and Methods. (B)
Compound dose-dependent inhibition of LARG (2 nM) stimulated RhoA (C189S) (500 nM)
guanine nucleotide binding at a 25 minute time point. (C) Chemical structures of the 5
compounds that show dose-dependent inhibition in panel B. Data in panel A and B were
measured in duplicate and represent mean ± SEM of three separate experiments (N = 3).
Data in panel B is represented as percent of DMSO control for [35S] GTPγS binding.
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Fig. 6. Compound Selectivity for LARG-stimulated RhoA [35S] GTPγS Binding
(A) Time-course of RhoA (C189S) (■) (500 nM) [35S] GTPγS binding over 180 minutes.
(B) Time-course of Gαo (●) (250 nM) [35S] GTPγS binding over 120 minutes. Both no
RhoA and no Gαo or [35S] GTPγS alone are represented by (■). (C) Bar graph
representation of compound (100 μM) selectivity for LARG-stimulated [35S] GTPγS
binding versus RhoA (C189S) and Gαo [35S] GTPγS binding. Binding was measured at a 60
minute time point (indicated by the dotted vertical line) for RhoA (C189S) and 25 minute
time point (indicated by the dotted vertical line and open circles) for both Gαo and LARG-
stimulated RhoA [35S] GTPγS binding. Data in panel A, B, and C were measured in
duplicate and represent mean ± SEM for three separate experiments (N = 3). Data in panel C
is represented as percent of DMSO control for [35S] GTPγS binding.
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